ISOPHARM LIMITED

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -19.1%

  £5,924,000 → £4,794,000

• Cash

  +119.3%

  £602,000 → £1,320,000

• Net assets

  +19.6%

  -£408,000 → -£328,000

• Employees

  -29.4%

  68 → 48

• Operating profit

  +106%

  -£1,058,000 → £64,000

• Profit before tax

  +107.6%

  -£1,057,000 → £80,000

• Wages

  -36.3%

  £2,581,000 → £1,643,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ISOPHARM LIMITED 2013-05-17 → present
2. ISOPHARM SENTRY LIMITED 2005-02-01 → 2013-05-17
3. SENTRY PRODUCTS LIMITED 1999-09-17 → 2005-02-01

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Abridged

Yes — abridged accounts (limited disclosure)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“On that basis, the directors have prepared these financial statements on a going concern basis. The company's parent undertaking, Lacker Midco Limited, has agreed to support the company's future trading and all group companies have confirmed they will not request repayment of amounts outstanding at the year end unless working capital allows for this.”

Significant events

• “As part of a strategic review of ongoing operations, the Group decided to dispose of the lab operation of the business. The sale of the operation was concluded in June 2024 for proceeds of £600,000 and net assets totalling £230,000 were transferred upon completion.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.